Table 1 Characteristics of patients in resolved group.
| Patient | Age | Sex | Location of classic CNV | Relation of classic CNV to polypoidal lesion | LS (μm) | PDT treatments, n | BCVA at baseline | BCVA at final visit | Follow‐up duration (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 80 | F | Juxtafovea | Adjacent | 2900 | 1 | 20/250 | 20/50 | 22 |
| 2 | 73 | M | Juxtafovea | Adjacent | 750 | 1 | 20/70 | 20/25 | 21 |
| 3 | 70 | F | Subfovea | Adjacent | 2650 | 1 | 20/130 | 20/30 | 21 |
| 4 | 68 | M | Subfovea | Adjacent | 3000 | 3 | 20/70 | 20/50 | 18 |
| 5 | 50 | M | Juxtafovea | Adjacent | 2450 | 1 | 20/130 | 20/200 | 17 |
| 6 | 68 | M | Juxtafovea | Adjacent | 1330 | 2 | 20/30 | 20/15 | 15 |
| 7 | 56 | M | Subfovea | Adjacent | 3060 | 1 | 20/100 | 20/20 | 14 |
| 8 | 63 | F | Juxtafovea | Adjacent | 1900 | 1 | 20/30 | 20/13 | 14 |
| 9 | 80 | M | Subfovea | Adjacent | 2090 | 1 | 20/130 | 20/300 | 13 |
| 10 | 68 | M | Juxtafovea | Adjacent | 1960 | 2 | 20/50 | 20/40 | 13 |
| 11 | 80 | M | Subfovea | Adjacent | 2100 | 2 | 20/220 | 20/200 | 12 |
| 12 | 80 | M | Juxtafovea | Adjacent | 3600 | 1 | 20/40 | 20/35 | 10 |
| 13 | 90 | M | Juxtafovea | Separated | 2750 | 1 | 20/70 | 20/35 | 8 |
| 14 | 59 | M | Subfovea | Adjacent | 2300 | 1 | 20/500 | 20/35 | 5 |
CNV, choroidal neovascularisation; LS, lesion size; PDT, photodynamic therapy; BCVA, best‐corrected visual acuity.
Adjacent, adjacent to polypoidal lesions; separated, separated from polypoidal lesions.